AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that it will give a live streamed update focusing on its project platform Painless on May 11 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Anders Hedlund, analyst at Redeye.
Martin Jönsson, CEO, together with Märta Segerdahl, CMO, Pontus Forsell, Head of Discovery & Research, and Johan Sandin, CSO, will present the Painless platform and the progress made in the projects, with recent positive clinical results from the phase Ib trial with ACD440, which is focused on neuropathic pain, and advancements made in the preclinical project TrkA-NAM for osteoarthritic pain and other severe pain disorders. These projects complement AlzeCure’s broad Alzheimer’s portfolio.
Watch the livestream on May 11 at 09:00 CEST via:
https://www.redeye.se/events/809997/strategy-update-alzecure-pharma
The presentation will be held in English and will be available on the company's website afterwards at: https://www.alzecurepharma.se/sv/presentationer-och-intervjuer/.